1. White House pressures FDA on unproven Japanese drug for COVID— As Covid-19 hinders clinical trial operations, research staff are finding themselves out of work— Aspen Neuro adds $70M to test Parkinson's cell therapy — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

It is over

Discussion in 'Neurocrine' started by anonymous, Dec 14, 2019 at 1:51 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    On December 14, 2019, Pfizer announced 11 BILLION acquisition agreement with Neurocrine Biosciences, Inc. (NBIX) to develop and market first-in-class treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, a clinical stage selective Nav1.6 sodium channel inhibitor with potential in SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other forms of epilepsy, including focal epilepsy.
     

  2. anonymous

    anonymous Guest

    Where did you see this information?
     
  3. anonymous

    anonymous Guest

    Avanair news blog
     
  4. anonymous

    anonymous Guest

    We acquired a shit epilepsy product. I asked former Epileptologist that I used to call on and they said it’s a terd. Great another crap drug
     
  5. anonymous

    anonymous Guest

    Yes, if you are an old fart at this company, Pfizer will make sure you get laid off.